Protocol Ledger

NCT06397911 · Phase II · RECRUITING

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

Interventional Phase II clinical trial protocol NCT06397911 sponsored by Oneness Biotech Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-08-08 Enrollment: 114 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06397911
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)114 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06397911
Protocol FieldVerified Registry Value
NCT IdentifierNCT06397911
Consolidated Lead SponsorOneness Biotech Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment114 participants (ESTIMATED)
Registered Start Date2024-08-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06397911
Hospital Research SiteLocationSite Profile
First OC DermatologyFountain Valley, CAOpen Hospital Dossier ->
Center for Dermatology Clinical Research, Inc.Fremont, CAOpen Hospital Dossier ->
UC Davis Comprehensive Cancer CenterSacramento, CAOpen Hospital Dossier ->
Kaohsiung Chang Gung Memorial HospitalKaohsiung City, TaiwanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI